Skanska gets $45m contract to refit US GSK R&D hub

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmacology, Clinical trial, Pharmaceutical industry, Gsk

GSK has hired Skanska AB to renovate its laboratory and office in Upper Providence, Pennsylvania, US in a $45m (€42m) project.

The deal will see the Sweden-headquartered construction firm demolish four floors of the Collegeville facility and build out of 9,300 square meters of Lab space.

The project will start later this month is due to be completed next October.

The Upper Providence lab became one GSK’s two drug discovery hubs in 2015​ – the other being at its headquarters in Stevenage – after the completion of a long running consolidation project.

GSK spokeswoman Mary Anne Rhyne told us: “This is the second phase of an update to our labs. We moved into other updated labs this fall and have found the redesign quite helpful.​”

According to the UK, activities at the US lab include target identification, safety studies, active pharmaceutical ingredient (API) manufacture, clinical trial drug manufacture, clinical trial management, medical oversight and regulatory interactions.

Growth plan

The project will be carried out by Skanska USA, a subsidiary that helps the firm’s pharmaceutical and biotechnology clients build facilities that comply with US Food and Drug Administration (FDA) regulations.

By 2018, 40 percent of GlaxoSmithKline's global drug R&D team will be based in Collegeville.

R&D scientists from GSK’s facilities in Upper Merion, Pennsylvania and Research Triangle Park, N.C., will relocate to Upper Providence.

The UK drug manufacturer has said the headcount at the site will increase from 1,600 to 3,200 before 2018.

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Case Study: SmartSignals eConsent

Case Study: SmartSignals eConsent

Signant Health | 15-Feb-2022 | Case Study

Signant’s eConsent solution helped a sponsor manage the consenting process complexities in their pediatric attention deficit hyperactivity disorder (ADHD)...

Related suppliers

Follow us


View more